United Therapeutics Corp - Company Profile
Powered by 
All the sales intelligence you need on United Therapeutics Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how United Therapeutics Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with United Therapeutics Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
United Therapeutics Corp (United Therapeutics) is a biotechnology company that focuses on the research, development, and manufacturing of treatments for pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease, neuroblastoma, and end-stage lung disease through the brands Tyvaso, Remodulin, Orenitram, Adcirca, and Unituxin. The company also offers LBE 360 transplant support service, a centralized ex vivo lung perfusion (EVLP) service model in the United States dedicated to making more donor organs available for transplant. . United Therapeutics collaborates with healthcare providers and specialty pharmacies to distribute its products. The company operates facilities in the US, Canada, and the UK. United Therapeutics is headquartered in Silver Spring, Maryland, the US.
Headquarters
United States of America
Address
1000 Spring Street, Silver Spring, Maryland, 20910
Website
www.unither.com
Telephone
1 301 6089292
No of Employees
1,400
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
UTHR (NASD)
Revenue (2024)
$3.2B
10.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
11.7%
(2024 vs 2023)
Market Cap*
$23.9B
Net Profit Margin (2024)
XYZ
1.0%
(2024 vs 2023)
* As of and is in US$
United Therapeutics Corp premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Treprostinil | Patient Support Program | - |
| Tadalafil | Therapy Initiation Platform | Tyvaso |
| Dinutuximab | Transplant Support Service | Remodulin |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In April, the company received the approval of the U.S. Food and Drug Administration for the company’s investigational miroliverELAP. |
| 2025 | Regulatory Approval | In February, the company received the U.S. Food and Drug Administration (FDA) clearance for its new investigational new drug application for the Ukidney xenotransplantation clinical trial. |
| 2024 | Contracts/Agreements | In August, the company collaborated with Robinson Helicopters to develop a fleet of hydrogen-powered helicopters for delivering synthetic human organs for transplant. |
Competitor Comparison
| Key Parameters | United Therapeutics Corp | Johnson & Johnson | Merck & Co Inc | Bristol-Myers Squibb Co | GSK plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
| City | Silver Spring | New Brunswick | Rahway | Princeton | London |
| State/Province | Maryland | New Jersey | New Jersey | New Jersey | England |
| No. of Employees | 1,400 | 138,200 | 75,000 | 32,500 | 66,841 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Martine A. Rothblatt | Chief Executive Officer; Chairperson | Executive Board | 1996 | 71 |
| James C. Edgemond | Chief Financial Officer; Treasurer | Senior Management | 2015 | 59 |
| Michael Benkowitz | President; Chief Operating Officer | Senior Management | 2016 | 54 |
| Paul A. Mahon | Secretary; General Counsel; Executive Vice President | Senior Management | 2023 | 62 |
| Christopher Causey | Director | Non Executive Board | 2003 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer